CV Sciences (CVSI) Asset Writedowns and Impairment (2013 - 2020)
CV Sciences (CVSI) reported Asset Writedowns and Impairment of $6.2 million for Q4 2020, up 3031.31% on a YoY basis from $198000.0 in Q1 2020, and up 3031.31% sequentially from $198000.0 in Q4 2019.
CV Sciences (CVSI) Asset Writedowns and Impairment (2013 - 2020) Analysis & Trends
CV Sciences (CVSI) has 7 years of Asset Writedowns and Impairment data on file, last reported at $6.2 million in Q4 2020.
- For the quarter ending Q4 2020, Asset Writedowns and Impairment rose 3031.31% year-over-year to $6.2 million; the trailing twelve-month figure through Dec 2020 stood at $6.4 million (up 2613.56% YoY), and the FY2023 full-year result was $251000.0, down 79.66% from the prior year.
- Asset Writedowns and Impairment grew to $6.2 million in Q4 2020, from $198000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $6.2 million in Q4 2020 to a low of -$47000.0 in Q4 2018.
- A 5-year average of $631384.2 and a median of $32000.0 in 2019 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment sank 156.92% in 2018 and soared 3300.0% in 2019, its largest moves.
- Tracing CVSI's Asset Writedowns and Impairment over 5 years: stood at $31003.0 in 2016, then jumped by 166.31% to $82565.0 in 2017, then slumped by 156.92% to -$47000.0 in 2018, then soared by 521.28% to $198000.0 in 2019, then soared by 3031.31% to $6.2 million in 2020.
- Business Quant data shows CVSI's Asset Writedowns and Impairment at $6.2 million in Q4 2020, $198000.0 in Q4 2019, and $6000.0 in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.20 Bn | 1.97 Bn |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.01 Bn | 20.85 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.41 Bn | 18.61 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.66 Bn | 12.23 Bn | 785.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 6.20 Mn |
| Dec 31, 2020 | 6.20 Mn |
| Dec 31, 2019 | 198,000.00 |
| Dec 31, 2019 | 198,000.00 |
| Sep 30, 2019 | 6,000.00 |
| Sep 30, 2019 | 6,000.00 |
| Jun 30, 2019 | 32,000.00 |
| Jun 30, 2019 | 32,000.00 |
| Dec 31, 2018 | -47,000.00 |
| Dec 31, 2018 | -47,000.00 |
| Sep 30, 2018 | 40,223.00 |
| Sep 30, 2018 | 40,223.00 |
| Jun 30, 2018 | -1,000.00 |
| Jun 30, 2018 | -1,000.00 |
| Mar 31, 2018 | 3,000.00 |
| Mar 31, 2018 | 3,000.00 |
| Dec 31, 2017 | 82,565.00 |
| Dec 31, 2017 | 82,565.00 |
| Jun 30, 2017 | 400,435.00 |
| Jun 30, 2017 | 400,435.00 |